

Edgar Filing: HALOZYME THERAPEUTICS INC - Form 8-K

HALOZYME THERAPEUTICS INC
Form 8-K
March 17, 2004

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) March 12, 2004

HALOZYME THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)

Nevada

000-49616

88-0488686

(State or other jurisdiction of (Commission File Number) (IRS Employer
incorporation) Identification No.)

11588 Sorrento Valley Road, Suite 17
San Diego, California 92121
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code (858) 794-8889

Not Applicable
(Former name or former address, if changed since last report)

Item 4. Changes in Registrant's Certifying Accountant

(a) (1) Previous independent accountants.

(i) On March 12, 2004, the Company dismissed Hall & Company ("Hall") as its independent accountants.

(ii) The reports of Hall on the financial statements of the Company for each of the past two fiscal years contained no adverse opinion or a disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope or accounting principles.

(iii) The decision to change independent accountants was approved by the Company's Board of Directors.

(iv) During the Company's two most recent fiscal years and through the date of this Report, the Company has had no disagreements with Hall on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of Hall,

Edgar Filing: HALOZYME THERAPEUTICS INC - Form 8-K

would have caused it to make reference to the subject matter of such disagreements in its report on the financial statements of the Company for such periods.

(v) During the Company's two most recent fiscal years and through the date of this Report, the Company has had no reportable events under Item 304(a) (1) (v) of Regulation S-K.

The Company has requested that Hall furnish it with a letter addressed to the Commission stating whether or not it agrees with the above statements. A copy of such letter, dated March 12, 2004, is filed as Exhibit No. 16.1 to this Form 8-K.

(2) New independent accountants.

The Company engaged Cacciamatta Accountancy Corporation ("Cacciamatta") as its new independent accountants as of March 12, 2004. During the two most recent fiscal years and through the date of their engagement by the Company, the Company did not consult with Cacciamatta regarding issues of the type described in Item 304(a) (2) of Regulation S-K.

Item 7. Financial Statements and Exhibits

Exhibit No.	Description
16.1	Letter from Hall & Company to the Securities and Exchange Commission

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Halozyne Therapeutics, Inc.

By: /s/ Jonathan E. Lim, MD

President and Chief Executive Officer

Date: March 12, 2004